Pharmaceutical Firms

Online pharmacies, drug wholesalers under scanner; non-compliance may lead penalties, license cancellations

In the past one month, the stock price of pharmaceuticals company has gained 15 per cent, as compared to 11 per cent decline in the BSE Sensex.

Uttar Pradesh is ramping up investments in pharma parks and medical device manufacturing to emerge as a major healthcare production hub in South Asia

Firms may shift to doctor outreach, CME programmes and patient support initiatives as CDSCO bars advertising of GLP-1 drugs ahead of semaglutide patent expiry

In the past four trading days, the stock price of Natco Pharma has surged 10 per cent after the company announced the launch of Pomalidomide Capsules (generic of Pomalyst) in the US market.

Emcure Pharmaceuticals stock was quoting close to its 52-week high of ₹1,585.50 on Monday, and has surged up to 62% in the last one year.

The Indian pharmaceutical market posted 11% growth in February 2026, driven by strong therapy performance, while Mounjaro remained India's highest-selling drug by value for a fifth month

Indian CDMOs are expanding manufacturing capacity and investing in advanced technologies as global pharma companies increasingly outsource complex drug development and manufacturing work

Supported by solid demand, disciplined execution, and capex programs progressing as planned, Sai Life management remains confident in sustaining positive growth momentum.

Indian drugmakers are reviewing shipment schedules and inventories for West Asia as escalating tensions threaten sea and air routes, raising freight costs and risking supply delays

Cipla will hold 60% in the new JV with Kemwell Biopharma, aiming to develop, manufacture and commercialise biologics and biosimilars for global markets amid rising demand

ICRA expects Sai Life Sciences to maintain strong growth momentum over the medium term on the back of a healthy growth outlook for the industry, good product mix and deepening customer engagement.

In a move aimed at speeding up approvals for new drugs, the government has changed the way testing permissions are granted, allowing companies to begin laboratory testing immediately after filing applications instead of waiting for detailed scrutiny. In an official circular, the country's apex drug regulatory authority, Central Drugs Standard Control Organization (CDSCO), said it has decided that "No Objection Certificate (NOC) for testing of drug samples at the designated laboratories (IPC, Ghaziabad; CDTL, Mumbai; CDL at CRI, Kasauli; or NIB, Noida) shall be issued immediately upon receipt of applications in the concerned division." Earlier, the regulator examined detailed specifications submitted by applicants before issuing permission for testing. These included "Type of formulation, dosage form, Critical Quality Attributes (CQAs), and general characteristics of the product," along with "Product development reports, forced degradation studies, and other relevant data, in ...

Morepen Labs has secured a ₹825 crore multi-year CDMO mandate from a global pharma major, with supplies set to begin in 4-5 months and execution running through Q1 FY27

Morepen Laboratories said supplies under the contract are expected to begin within the next four to five months, while execution is scheduled through the first quarter of the financial year 2026-27

The settlement resolves Lupin's ‌pending litigation with Astellas and ​enables the company to continue marketing Mirabegron in the United States

Industry says approval delays, weak clinical trial infra holding back sector

Sun Pharma will maintain a disciplined approach when it comes to acquisitions in order to allow the business to grow organically while remaining attractive for shareholders, according to Chairman Dilip Shanghvi. The Mumbai-based drug major is also evaluating biosimilar segments, he stated. "I think the US continues to be an important part of our focus, specifically for innovative medicines," Shanghvi said when asked about the company's M&A strategy in an analyst call. The company is interested in selling innovative medicines globally, he added. "For emerging markets, we are looking at what you call tuck-ins or smaller acquisitions, which we can look at integrating with our existing business to get scale in the emerging markets," he added. The drug major has consistently indicated that it wants to remain disciplined about acquisition, Shanghvi said. "Our focus is on finding a way to grow our business organically at a rate so that we continue to be an attractive investment ...

A customs duty exemption on select high-cost cancer and rare disease therapies is expected to lower treatment costs for patients while supporting demand for multinational and domestic pharma companies

FY27 PLI scheme allocation rises 2.24%, aiming to add 500 MT to domestic API production